Alpine Immune Sciences Inc., will merge with a wholly owned Nivalis subsidiary in an all-stock transaction announced April 18. The companies said the deal creates a combined entity with a novel protein-based platform focused on inflammation and immunooncology. The combined company is expected to have roughly $90 million in cash and cash equivalents when the deal closes—expected to occur in third quarter of this year pending stockholder approvals and other customary conditions.

Carin M. Cutler, a partner resident in the Boulder and Denver, Colorado offices, led the Ballard Spahr attorneys advising Nivalis.

Read the full article here. Subscription may be required.

Related Areas